JP2019535295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535295A5 JP2019535295A5 JP2019528462A JP2019528462A JP2019535295A5 JP 2019535295 A5 JP2019535295 A5 JP 2019535295A5 JP 2019528462 A JP2019528462 A JP 2019528462A JP 2019528462 A JP2019528462 A JP 2019528462A JP 2019535295 A5 JP2019535295 A5 JP 2019535295A5
- Authority
- JP
- Japan
- Prior art keywords
- probe
- base length
- nucleotides
- ligated product
- length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 17
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 239000000523 sample Substances 0.000 claims 10
- 230000002759 chromosomal effect Effects 0.000 claims 7
- 230000003993 interaction Effects 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 108091008146 restriction endonucleases Proteins 0.000 claims 3
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001973 epigenetic effect Effects 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000033832 Eosinophilic Acute Leukemia Diseases 0.000 claims 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 1
- 101000846284 Homo sapiens Pre-mRNA 3'-end-processing factor FIP1 Proteins 0.000 claims 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100031755 Pre-mRNA 3'-end-processing factor FIP1 Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 210000004940 nucleus Anatomy 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 238000011895 specific detection Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022183117A JP7579003B2 (ja) | 2016-12-01 | 2022-11-16 | がんの診断における後成的染色体相互作用の応用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428893P | 2016-12-01 | 2016-12-01 | |
| US62/428,893 | 2016-12-01 | ||
| PCT/GB2017/053615 WO2018100381A1 (en) | 2016-12-01 | 2017-11-30 | Application of epigenetic chromsomal interactions in cancer diagnostics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022183117A Division JP7579003B2 (ja) | 2016-12-01 | 2022-11-16 | がんの診断における後成的染色体相互作用の応用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535295A JP2019535295A (ja) | 2019-12-12 |
| JP2019535295A5 true JP2019535295A5 (https=) | 2021-01-14 |
Family
ID=60702831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528462A Pending JP2019535295A (ja) | 2016-12-01 | 2017-11-30 | がんの診断における後成的染色体相互作用の応用 |
| JP2022183117A Active JP7579003B2 (ja) | 2016-12-01 | 2022-11-16 | がんの診断における後成的染色体相互作用の応用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022183117A Active JP7579003B2 (ja) | 2016-12-01 | 2022-11-16 | がんの診断における後成的染色体相互作用の応用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11560597B2 (https=) |
| EP (2) | EP4357463A3 (https=) |
| JP (2) | JP2019535295A (https=) |
| KR (1) | KR102481242B1 (https=) |
| CN (1) | CN110234769B (https=) |
| AU (1) | AU2017367245B2 (https=) |
| CA (1) | CA3045070A1 (https=) |
| ES (1) | ES2971286T3 (https=) |
| MY (1) | MY190153A (https=) |
| PL (1) | PL3548633T3 (https=) |
| TW (1) | TWI865427B (https=) |
| WO (1) | WO2018100381A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230049379A1 (en) * | 2019-05-08 | 2023-02-16 | Oxford BioDynamics PLC | Chromosome conformation markers of prostate cancer and lymphoma |
| CN118506860B (zh) * | 2024-07-18 | 2024-10-08 | 广州女娲生命科技有限公司 | 药物表观遗传安全性评价的检测分析方法及系统 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2614118C (en) * | 2005-07-04 | 2013-11-26 | Erasmus University Medical Center | 4c |
| GB0603251D0 (en) * | 2006-02-17 | 2006-03-29 | Isis Innovation | DNA conformation |
| US8642295B2 (en) * | 2007-01-11 | 2014-02-04 | Erasmus University Medical Center | Circular chromosome conformation capture (4C) |
| CA2609172A1 (en) * | 2007-10-31 | 2009-04-30 | University Of Utah Research Foundation | Immunotherapy compositions for use with targeted therapy in the treatment of cancer |
| GB0810051D0 (en) | 2008-06-02 | 2008-07-09 | Oxford Biodynamics Ltd | Method of diagnosis |
| US9434985B2 (en) * | 2008-09-25 | 2016-09-06 | University Of Massachusetts | Methods of identifying interactions between genomic loci |
| WO2010059742A1 (en) * | 2008-11-18 | 2010-05-27 | Collabrx, Inc. | Individualized cancer treatment |
| WO2012005595A2 (en) * | 2010-07-09 | 2012-01-12 | Wouter Leonard De Laat | V3-d genomic region of interest sequencing strategies |
| EP2678359A4 (en) * | 2011-02-24 | 2015-01-28 | Merrimack Pharmaceuticals Inc | COMBINATION THERAPIES WITH ANTI-ERBB3 MEDIUM |
| US8663919B2 (en) * | 2011-05-18 | 2014-03-04 | Life Technologies Corporation | Chromosome conformation analysis |
| JP6280546B2 (ja) * | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| CN102827935B (zh) * | 2012-08-29 | 2013-12-18 | 北京大学人民医院 | 定量检测FIP1L1-PDGFRA融合基因mRNA水平的试剂盒 |
| GB201320351D0 (en) * | 2013-11-18 | 2014-01-01 | Erasmus Universiteit Medisch Ct | Method |
| US11802305B2 (en) | 2015-06-24 | 2023-10-31 | Oxford BioDynamics PLC | Detection processes using sites of chromosome interaction |
| WO2017106290A1 (en) | 2015-12-14 | 2017-06-22 | The General Hospital Corporation | Methods of detecting insulator dysfunction and oncogene activation for screening, diagnosis and treatment of patients in need thereof |
| GB201608000D0 (en) | 2016-05-06 | 2016-06-22 | Oxford Biodynamics Ltd | Chromosome detection |
-
2017
- 2017-11-30 MY MYPI2019002870A patent/MY190153A/en unknown
- 2017-11-30 WO PCT/GB2017/053615 patent/WO2018100381A1/en not_active Ceased
- 2017-11-30 PL PL17817030.4T patent/PL3548633T3/pl unknown
- 2017-11-30 ES ES17817030T patent/ES2971286T3/es active Active
- 2017-11-30 EP EP23217260.1A patent/EP4357463A3/en active Pending
- 2017-11-30 CA CA3045070A patent/CA3045070A1/en active Pending
- 2017-11-30 EP EP17817030.4A patent/EP3548633B1/en active Active
- 2017-11-30 KR KR1020197019088A patent/KR102481242B1/ko active Active
- 2017-11-30 CN CN201780085308.2A patent/CN110234769B/zh active Active
- 2017-11-30 JP JP2019528462A patent/JP2019535295A/ja active Pending
- 2017-11-30 US US16/465,133 patent/US11560597B2/en active Active
- 2017-11-30 AU AU2017367245A patent/AU2017367245B2/en active Active
- 2017-12-01 TW TW106142279A patent/TWI865427B/zh active
-
2022
- 2022-10-28 US US18/050,795 patent/US20230082230A1/en active Pending
- 2022-11-16 JP JP2022183117A patent/JP7579003B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12534754B2 (en) | Attenuators | |
| US11332778B2 (en) | Methods and systems for nucleic acid amplification | |
| JP2009526543A5 (https=) | ||
| JP2018524993A5 (https=) | ||
| GB2595076A (en) | Methods for targeted nucleic acid library formation | |
| JP2019537439A5 (https=) | ||
| JP2018514230A5 (https=) | ||
| JP2014504880A5 (https=) | ||
| JP2013532494A5 (https=) | ||
| JP2017510244A5 (https=) | ||
| JP2016537990A5 (https=) | ||
| JP6783861B2 (ja) | 等温核酸増幅のためのレポーター染料、クエンチャーが含まれる等温ベースの二重機能性オリゴヌクレオチド及びそれを用いた核酸増幅並びに測定方法 | |
| Lee et al. | Three-way junction-induced isothermal amplification for nucleic acid detection | |
| JP2013507992A5 (https=) | ||
| JP2014030431A5 (https=) | ||
| WO2015063154A1 (en) | Blocking primers in multiplex pcr based assays | |
| JP2016527900A5 (https=) | ||
| US20170335375A1 (en) | Kit and method for detection of microrna | |
| JPWO2020106906A5 (https=) | ||
| JP2019535295A5 (https=) | ||
| WO2013107287A1 (zh) | 连接酶反应介导的扩增方法及用途 | |
| JP2014533502A5 (https=) | ||
| JP2021509814A5 (https=) | ||
| JP2016527904A5 (https=) | ||
| Yang et al. | A tailored LNA clamping design principle: Efficient, economized, specific and ultrasensitive for the detection of point mutations |